The Effects of Connective Tissue Manipulation in Primary Dysmenorrhea
Mots clés
Abstrait
La description
Primary dysmenorrhea is defined as cramping pain in the lower abdomen that occurs before or during menstruation without identifiable pelvic pathology. Secondary symptoms include nausea, vomiting, fatigue, back pain, headaches, dizziness, and diarrhea. Primary dysmenorrhea has been reported as the leading cause of recurrent absenteeism from school or work in adolescent girls and young women, and it is considered to be a common disorder among women of reproductive age. The greater percentages of depression and anxiety are more common in patients with severe dysmenorrhea compared to those without dysmenorrhea. The prevalence of dysmenorrhea varies between 25-97%, and approximately 20% of them have severe pain.
Treatment in primary dysmenorrhea can be classified as pharmacological, non-pharmacological and complementary therapies. Pharmacological therapies focus on the reduction of menstrual pain and relaxation of the uterine muscles with non-steroidal anti-inflammatory drugs (NSAIDs) or oral contraceptive pills. Management of dysmenorrhea with these pharmacological agents is associated with side effects such as nausea, breast tenderness, inter-menstrual bleeding and auditory and visual disturbances. Therefore, non-pharmacological approaches are needed in the treatment of dysmenorrhea. Non-pharmacological approaches to relieve dysmenorrhea symptoms include acupuncture, reflexology, biofeedback, transcutaneous electrical stimulation, relaxation therapy, massage therapy, and exercise. Complementary therapies include essential fatty acids, vitamins, herbal medicine, and aromatherapy. It has been known that previous studies investigating the efficacy of these approaches in primary dysmenorrhea do not have a control or placebo-control group or they reveal the effectiveness of combined applications.
Connective tissue manipulation is a manually administered reflex therapy or a massage application. It may target superficial connective tissues and may stimulate segmental and supra-segmental autonomic cutaneous-visceral reflexes to restore autonomic balance and reduce dysfunction in affected internal organs. Therefore, connective tissue manipulation can be used to increase circulation of the uterus by stimulating segmental reflexes and to reduce congestion and menstrual pain. Although the effect of connective tissue massage on a wide range of health problems such as painful syndromes, vascular problems or bowel dysfunction is investigated, there is limited evidence of its use in primary dysmenorrhea. There is no randomized placebo-controlled study investigating the effects of connective tissue massage on menstrual pain and symptoms of dysmenorrhea. Therefore, the aim of the present study is to determine the effectiveness of connective tissue massage by the randomized placebo-controlled design in patients with primary dysmenorrhea.
Rendez-vous
Dernière vérification: | 03/31/2019 |
Première soumission: | 04/10/2019 |
Inscription estimée soumise: | 04/10/2019 |
Première publication: | 04/11/2019 |
Dernière mise à jour soumise: | 04/11/2019 |
Dernière mise à jour publiée: | 04/15/2019 |
Date de début réelle de l'étude: | 09/30/2018 |
Date d'achèvement primaire estimée: | 09/30/2020 |
Date estimée d'achèvement de l'étude: | 09/30/2020 |
Condition ou maladie
Intervention / traitement
Other: intervention
Other: placebo ultrasound
Phase
Groupes d'armes
Bras | Intervention / traitement |
---|---|
Active Comparator: intervention connective tissue manipulation | Other: intervention From the estimated date of ovulation to the onset of menstrual bleeding, connective tissue massage will be applied to the sacral, lumbar, lower thoracic and anterior pelvic regions for 5 days per week. The application will take 10 min. During the massage treatment, the physiotherapist will touch the end of the middle finger with the skin of the patient and apply the skin to the pull. The patient will be in the supine position during the treatment of the anterior pelvic region while the patient is in the sitting position during the treatment of the back area. |
Placebo Comparator: placebo ultrasound placebo ultrasound | Other: placebo ultrasound From the estimated date of ovulation to the beginning of the next menstrual bleeding, placebo ultrasound will be applied a total of 10 minutes (5 minutes for sacral and lumbar, and lower thoracic regions and 5 min for the anterior pelvic region). Placebo ultrasound application will be performed with superficial circular movements without applying excessive pressure. During the application, the device will only be switched on, the dose will not be adjusted and the patient will be given an image of ultrasound dose. |
No Intervention: control control group |
Critère d'éligibilité
Âges éligibles aux études | 18 Years À 18 Years |
Sexes éligibles à l'étude | Female |
Accepte les bénévoles en santé | Oui |
Critères | Inclusion Criteria: - Being volunteer to participate in the study - Having regular menstrual cycles (28 ± 7 days) - Being nulliparous - Having history of the onset of menstrual pain in the first few years after menarche - Considering the last 6 months, pain intensity >4 on the Visual Analog Scale. Exclusion Criteria: - Severe gastrointestinal, urogynecologic or autoimmune disease, other chronic pain syndromes, psychiatric disorder - Pregnancy - Use of intrauterine device - Use of pharmacologic agents (except analgesics or non-NSAID) or non-pharmacological agent - Urogynecological surgery - Oral contraceptive or antidepressant use during the last 6 months - Having an irregular menstrual cycle - Endometriosis associated with suspected dysmenorrhea, pathologic condition associated with uterine pain such as fibroids, or ultrasonographic examination |
Résultat
Mesures des résultats primaires
1. Pain intensity [change from baseline pain intensity to 6 months]
Mesures des résultats secondaires
1. Anxiety level [change from baseline anxiety level to 6 months]
2. Psychological status [change from baseline psychological status to 6 months]
3. Self-reported improvement [change from baseline self-reported improvement to 6 months]